Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MECP2 | P51608 | 1/20 | 0.46 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.46 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.46 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.46 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29932950 | 0.79 | KDR (1.00) | KDRLCKKMT2AMEN1MAPK10 | |
| SCHEMBL13701559 | 0.79 | KDR (1.00) | KDRLCKKMT2AMEN1MAPK10 | |
| SCHEMBL2065572 | 0.79 | KDR (1.00) | KDRLCKKMT2AMEN1MAPK10 | |
| SCHEMBL2868326 | 0.79 | KDR (0.65) | KDRLCKKMT2AMEN1MAPK10 | |
| SCHEMBL7569208 | 0.79 | KDR (0.78) | KDR | |
| SCHEMBL7487695 | 0.79 | KDR (0.65) | KDRLCK | |
| Hydrochloric Acid SCHEMBL2861232 | 0.78 | KDR (0.63) | KDRLCKKMT2AMEN1MAPK10 | |
| SCHEMBL6179920 | 0.77 | KDR (1.00) | KDRLCK | |
| SCHEMBL15401541 | 0.76 | KDR (0.61) | KDRLCKKMT2AMEN1MAPK10 | |
| SCHEMBL6704817 | 0.76 | KDR (0.65) | KDRLCKKMT2AMEN1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218376-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030064996-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| EP-1218376-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1218376-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147203-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885LCK 16/4885KMT2A 3298/4885 |
| US-20030064996-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885LCK 16/4885KMT2A 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.